Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables
Lung cancer is one of the most frequently occurring neoplasms and usually has a poor prognosis because most of the patients present with advanced or metastatic disease at the time of diagnosis. Numerous prognostic factors (PFs) have been studied, but the two most prominent, having both prognostic an...
Main Authors: | Thierry Berghmans, Marianne Paesmans, Jean-Paul Sculier |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834011401951 |
Similar Items
-
A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
by: Thierry Berghmans, et al.
Published: (2017-09-01) -
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis
by: Vallot Frédéric, et al.
Published: (2001-06-01) -
Advances in target therapy in lung cancer
by: Jean-Paul Sculier, et al.
Published: (2015-03-01) -
Are intensive cares worthwhile for breast cancer patients: the experience of an oncological ICU.
by: Virginie Destrebecq, et al.
Published: (2016-10-01) -
Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study
by: T. Berghmans, et al.
Published: (2005-12-01)